Jean-Louis Paillasseur
Overview
Explore the profile of Jean-Louis Paillasseur including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
545
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Burgel P, Paillasseur J, Durieu I, Reynaud-Gaubert M, Hamidfar R, Murris-Espin M, et al.
Ann Am Thorac Soc
. 2024 Apr;
21(7):1053-1064.
PMID: 38579175
Limited data exist on the safety and effectiveness of elexacaftor-tezacaftor-ivacaftor (ETI) in people with cystic fibrosis (pwCF) and advanced lung disease. To evaluate the effects of ETI in an unselected...
2.
Martin C, Reynaud-Gaubert M, Hamidfar R, Durieu I, Murris-Espin M, Danner-Boucher I, et al.
J Cyst Fibros
. 2022 Feb;
21(3):489-496.
PMID: 35123901
Background: Elexacaftor-tezacaftor-ivacaftor induces rapid clinical improvement in patients with cystic fibrosis (CF) and advanced pulmonary disease, often leading to suspend the indication for lung transplantation. Yet no long-term data is...
3.
Reix P, Tatopoulos A, Ioan I, Le Bourgeois M, Bui S, Choukroun M, et al.
J Cyst Fibros
. 2021 Jun;
21(1):155-159.
PMID: 34183285
Lung clearance index (LCI) is a biomarker of ventilation inhomogeneity. Data are scarce on its usefulness in daily practice for monitoring the effects of treatments in older children and adults...
4.
Zysman M, Deslee G, Perez T, Burgel P, Le Rouzic O, Brinchault-Rabin G, et al.
Int J Chron Obstruct Pulmon Dis
. 2021 May;
16:1275-1284.
PMID: 34007166
Background: Chronic respiratory failure may occur as a consequence of chronic obstructive pulmonary disease (COPD) and is associated with significant morbidity and mortality. Hypoxemia is determined by underlying disease characteristics...
5.
Burgel P, Da Silva J, Paillasseur J, Martin C
Am J Respir Crit Care Med
. 2021 May;
204(3):372-374.
PMID: 33951399
No abstract available.
6.
Burgel P, Durieu I, Chiron R, Ramel S, Danner-Boucher I, Prevotat A, et al.
Am J Respir Crit Care Med
. 2021 Feb;
204(1):64-73.
PMID: 33600738
Elexacaftor-tezacaftor-ivacaftor is a CFTR (cystic fibrosis [CF] transmembrane conductance regulator) modulator combination, developed for patients with CF with at least one Phe508del mutation. To evaluate the effects of elexacaftor-tezacaftor- ivacaftor...
7.
Burgel P, Durieu I, Chiron R, Mely L, Prevotat A, Murris-Espin M, et al.
J Cyst Fibros
. 2020 Jun;
20(2):220-227.
PMID: 32591294
Background: Phase 3 trials have demonstrated the safety and efficacy of lumacaftor-ivacaftor (LUMA-IVA) in patients with cystic fibrosis (CF) homozygous for the Phe508del CFTR mutation and percent predicted forced expiratory...
8.
Burgel P, Munck A, Durieu I, Chiron R, Mely L, Prevotat A, et al.
Am J Respir Crit Care Med
. 2019 Oct;
201(2):188-197.
PMID: 31601120
Lumacaftor-ivacaftor is a CFTR (cystic fibrosis transmembrane conductance regulator) modulator combination recently approved for patients with cystic fibrosis (CF) homozygous for the Phe508del mutation. To evaluate the safety and effectiveness...
9.
Zysman M, Burgel P, Court-Fortune I, Brinchault-Rabin G, Nesme-Meyer P, Surpas P, et al.
Respir Res
. 2019 Aug;
20(1):191.
PMID: 31439045
Background: Although COPD affects both men and women, its prevalence is increasing more rapidly in women. Disease outcomes appear different among women with more frequent dyspnea and anxiety or depression...
10.
Perez T, Deslee G, Burgel P, Caillaud D, Le Rouzic O, Zysman M, et al.
Int J Chron Obstruct Pulmon Dis
. 2019 Jul;
14:1399-1410.
PMID: 31308646
The 6-min walk test (6MWT) allows exercise tolerance to be assessed, and it has a significant prognostic value in COPD. The goal of this study was to analyse the determinants...